<DOC>
	<DOCNO>NCT02971306</DOCNO>
	<brief_summary>Alcoholic hepatitis relate high mortality rate . About 40 % patient die within first 6 month detection clinical syndrome . Therefore , essential proper diagnosis early treatment . In response acute chronic liver damage , bone marrow derive stem cell spontaneously populate liver differentiate hepatic cell . Animal human study suggest injured hepatocyte may replace pluripotent bone marrow cell . However , hepatocyte repopulation highly dependent variety liver injury therapeutic conditions6 . The study suggest Granulocyte-colony stimulate factor ( G-CSF ) regenerate hepatocyte fuse hematopoietic cell , thereby enhance liver histology survival rate . G-CSF cytokine capable regulate number function neutrophil . In three recent study mobilization bone marrow stem cell induce G-CSF observe patient alcoholic hepatitis . In two study survival benefit use G-CSF . Alcoholism lead decrease endogenous antioxidant potential . Alcoholic liver disease ( ALD ) patient show low endogenous antioxidant . Chronic ethanol consumption cause selective deficiency availability reduce glutathione ( GSH ) mitochondrion report . This due impaired functioning GSH transporter cytosol mitochondrial matrix . The effect glutathione replenish potential N-acetyl cysteine ( NAC ) use reduce oxidative stress , also excellent safety profile . Therefore , NAC use severe alcoholic hepatitis treatment due therapeutic potential factor . NAC also inhibit apoptosis pro-inflammatory cytokine production . In study high dos intravenous N-acetyl cysteine therapy 14 day confer neither survival benefit early biological improvement severe alcoholic hepatitis patient adequate nutritional support.However , result must view caution , since study suffer lack power . In recent study , NAC corticosteroids combination therapy benefit among patient severe acute alcoholic hepatitis 1 month survival , although final outcome 6 month survival improve . There study use combination therapy NAC plus G-CSF patient severe alcoholic hepatitis . Therefore plan study safety efficacy combination therapy G-CSF NAC patient alcoholic hepatitis .</brief_summary>
	<brief_title>G-CSF Plus NAC In Severe Alcoholic Hepatitis</brief_title>
	<detailed_description>Patients severe alcoholic hepatitis , admit Department Hepatology PGIMER , Chandigarh July 2014 December 2016 include study . METHODS This open label trial . A randomization code generate random number table . The patient randomize receive standard medical therapy pentoxifylline control combination therapy Pentoxifylline NAC G-CSF case . There one control two case : 1 ) Pentoxifylline ( control ) 2 ) Pentoxifylline+G-CSF ( case 1 ) 3 ) Pentoxifylline+G-CSF +NAC ( case2 ) A ) Pentoxifylline 400 mg thrice daily 28 day A ) Pentoxifylline 400 mg thrice daily 28 day plus G-CSF 5 mcg/kg every 12 hourly consecutive 5 day A ) Pentoxifylline 400 mg thrice daily 28 day plus G-CSF 5 mcg/kg every 12 hourly 5 day plus NAC 300 mg/kg day 1 ( 150 mg/kg 250 ml 5 % dextrose minute 30 minutes,50 mg/kg 500ml 5 % dextrose period 4 hour , 100mg /kg 1000 ml 5 % dextrose period 16 hour ) day 2 5 100mg /kg/day 1000ml glucose solution . This single time therapy . Patients admit department hepatology assess everyday clinically well laboratory test therapy assess safety effect treatment . 1 . Total leukocytes count assess daily . 2 . Circulating CD 34 positive cell measure day 0 6 G-CSF therapy . 3 . In addition , ultrasonography perform day 1 6 order evaluate difference spleen size portal vein flow . 4 . Biochemical , coagulation , hematological parameter ( Liver function test , Renal Function Tests , Prothrombin Time , International Normalised Ratio , etc . ) monitor periodically , daily 1 week , weekly 1month monthly three month . All patient follow weekly interval 1 month monthly 3 month . Outcome : Primary Objectives : Survival 3 month Secondary Objectives : Mobilisation CD34 positive cell peripheral blood . Clinical/biochemical improvement liver function profile . Improvement prognostic scores-Maddrey 's Discriminant function , MELD score , Child score . Safety efficacy G-CSF NAC alcoholic hepatitis</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Alcoholic hepatitis patient : 1 . More 10 year heavy alcohol consumption ( mean intake ≈ 100 g/day ) . 2 . Elevated aspartate aminotransferase level ( &lt; 500 IU per millilitre ) Ratio ofAST/ALT≥2 time 3 . Elevated serum total bilirubin level ≥ 5 mgdL ( 86 μmol/L ) 4 . Elevated INR ( ≥1.5 ) 5 . Neutrophilia . Patient Maddrey 's DF of≥ 32 include study , without biopsy . 1 . Age &lt; 18 &gt; 75 year 2 . Hepatocellular carcinoma portal vein thrombosis 3 . Refusal participate study 4 . Serum creatinine &gt; 1.0 mg % 5 . Hepatic encephalopathy grade 3 4 6 . Upper gastrointestinal bleed last ten day 7 . Uncontrolled bacterial infection 8 . Human immunodeficiency virus , Hepatitis B virus , Hepatitis C virus seropositivity , Autoimmune hepatitis , hemochromatosis , Wilson 's disease , alpha1antitrypsin deficiency 9 . Pregnancy 10 . Glucocorticoid treatment 11 . Significant comorbidity 12 . Previous know hypersensitivity GCSF/NAC</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>alcoholic hepatitis</keyword>
	<keyword>alcoholic liver disease</keyword>
	<keyword>jaundice</keyword>
	<keyword>ascites</keyword>
	<keyword>regeneration</keyword>
</DOC>